Literature DB >> 28331095

Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies.

Shuangshuang Wang1,2, Huanhuan Ren1, Wenbo Jiang1, Honglin Chen3, Hongxing Hu1, Zhiwei Chen3, Paul Zhou4,2.   

Abstract

Recent studies have shown that Fc-Fcγ receptor (FcγR) interactions are required for in vivo protection against influenza viruses by broadly reactive anti-hemagglutinin (HA) stem, but not virus strain-specific, anti-receptor binding site (RBS), antibodies (Abs). Since only a few Abs recognizing epitopes in the head region but outside the RBS have been tested against single-challenge virus strains, it remains unknown whether Fc-FcγR interactions are required for in vivo protection by Abs recognizing epitopes outside the RBS and whether the requirement is virus strain specific or epitope specific. In the present study, we therefore investigated the requirements for in vivo protection using two pan-H5 Abs, 65C6 and 100F4. We generated chimeric Abs, 65C6/IgG2a and 100F4/IgG2a, which preferentially engage activating FcγRs, and isogenic forms, 65C6/D265A and 100F4/D265A, which do not bind FcγR. Virus neutralizing activity, binding, antibody-dependent cellular cytotoxicity (ADCC), and in vivo protection of these Abs were compared using three H5 strains, A/Shenzhen/406H/2006 (SZ06), A/chicken/Shanxi/2/2006 (SX06), and A/chicken/Netherlands/14015526/2014 (NE14). We found that all four chimeric Abs bound and neutralized the SZ06 and NE14 strains but poorly inhibited the SX06 strain. 65C6/IgG2a and 100F4/IgG2a, but not 65C6/D265A and 100F4/D265A, mediated ADCC against target cells expressing HA derived from all three virus strains. Interestingly, both 65C6/IgG2a and 65C6/D265A demonstrated comparable protection against all three virus strains in vivo; however, 100F4/IgG2a, but not 100F4/D265A, showed in vivo protection. Thus, we conclude that Fc-FcγR interactions are required for in vivo protection by 100F4, but not by 65C6, and therefore, protection is not virus strain specific but epitope specific.IMPORTANCE Abs play an important role in immune protection against influenza virus infection. Fc-FcγR interactions are required for in vivo protection by broadly neutralizing antistem, but not by virus strain-specific, anti-receptor binding site (RBS), Abs. Whether such interactions are necessary for protection by Abs that recognize epitopes outside RBS is not fully understood. In the present study, we investigated in vivo protection mechanisms against three H5 strains by two pan-H5 Abs, 65C6 and 100F4. We show that although these two Abs have similar neutralizing, binding, and ADCC activities against all three H5 strains in vitro, they have divergent requirements for Fc-FcγR interactions to protect against the three H5 strains in vivo The Fc-FcγR interactions are required for in vivo protection by 100F4, but not by 65C6. Thus, we conclude that Fc-FcγR interactions for in vivo protection by pan-H5 Abs is not strain specific, but epitope specific.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  in vivo protection; influenza viruses; monoclonal antibodies

Mesh:

Substances:

Year:  2017        PMID: 28331095      PMCID: PMC5432862          DOI: 10.1128/JVI.02065-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

2.  Corrigendum to 'Human influenza viruses and CD8+ T cell responses' [Curr. Opin. Virol. 16 (2016) 132-142].

Authors:  Emma J Grant; Sergio M Quiñones-Parra; E Bridie Clemens; Katherine Kedzierska
Journal:  Curr Opin Virol       Date:  2016-08       Impact factor: 7.090

3.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

4.  Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.

Authors:  Paul E Leon; Wenqian He; Caitlin E Mullarkey; Mark J Bailey; Matthew S Miller; Florian Krammer; Peter Palese; Gene S Tan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

5.  Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses.

Authors:  Yoshitaka Iba; Yoshifumi Fujii; Nobuko Ohshima; Tomomi Sumida; Ritsuko Kubota-Koketsu; Mariko Ikeda; Motoaki Wakiyama; Mikako Shirouzu; Jun Okada; Yoshinobu Okuno; Yoshikazu Kurosawa; Shigeyuki Yokoyama
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

6.  A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.

Authors:  Hongxing Hu; Jarrod Voss; Guoliang Zhang; Philippi Buchy; Teng Zuo; Lulan Wang; Feng Wang; Fan Zhou; Guiqing Wang; Cheguo Tsai; Lesley Calder; Steve J Gamblin; Linqi Zhang; Vincent Deubel; Boping Zhou; John J Skehel; Paul Zhou
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

7.  A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin.

Authors:  Jens C Krause; Tshidi Tsibane; Terrence M Tumpey; Chelsey J Huffman; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

8.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

9.  Viral receptor-binding site antibodies with diverse germline origins.

Authors:  Aaron G Schmidt; Matthew D Therkelsen; Shaun Stewart; Thomas B Kepler; Hua-Xin Liao; M Anthony Moody; Barton F Haynes; Stephen C Harrison
Journal:  Cell       Date:  2015-05-07       Impact factor: 41.582

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  5 in total

Review 1.  The Quest for a Truly Universal Influenza Vaccine.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Front Cell Infect Microbiol       Date:  2019-10-10       Impact factor: 5.293

Review 2.  The Vestigial Esterase Domain of Haemagglutinin of H5N1 Avian Influenza A Virus: Antigenicity and Contribution to Viral Pathogenesis.

Authors:  Zhiqiang Zheng; Subha Sankar Paul; Xiaobing Mo; Yu-Ren Adam Yuan; Yee-Joo Tan
Journal:  Vaccines (Basel)       Date:  2018-08-10

3.  Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.

Authors:  Joan E M van der Lubbe; Johan W A Verspuij; Jeroen Huizingh; Sonja P R Schmit-Tillemans; Jeroen T B M Tolboom; Liesbeth E H A Dekking; Ted Kwaks; Börries Brandenburg; Wim Meijberg; Roland C Zahn; Ramon Roozendaal; Harmjan Kuipers
Journal:  Front Immunol       Date:  2018-10-12       Impact factor: 7.561

4.  A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.

Authors:  Sandhya Bangaru; Heng Zhang; Iuliia M Gilchuk; Thomas G Voss; Ryan P Irving; Pavlo Gilchuk; Pranathi Matta; Xueyong Zhu; Shanshan Lang; Travis Nieusma; Juergen A Richt; Randy A Albrecht; Hillary A Vanderven; Robin Bombardi; Stephen J Kent; Andrew B Ward; Ian A Wilson; James E Crowe
Journal:  Nat Commun       Date:  2018-07-10       Impact factor: 14.919

5.  Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection.

Authors:  Zhiqiang Zheng; Su Hui Catherine Teo; Suganya Cheyyatraivendran Arularasu; Zhehao Liu; Nur Khairiah Mohd-Ismail; Chee Keng Mok; Chee Bing Ong; Justin Jang-Hann Chu; Yee-Joo Tan
Journal:  Emerg Microbes Infect       Date:  2020-01-06       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.